Home / Market News / $TXG
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Stifel Maintains Buy Rating and Raises Price Target for 10x Genomics

Nov 6, 2026, 2:35 PM UTC · Primary ticker $TXG

Stifel has increased its price target for 10x Genomics (TXG) to $68 from $50, while reiterating a Buy rating. This represents a significant 36% increase in the target price, suggesting a potential upside of 17.1% from the recent closing price, which could positively influence investor sentiment.

Stifel, a prominent financial services firm, has raised its price target for 10x Genomics (TXG) from $50 to $68, representing a substantial 36% increase. This upward revision, coupled with the maintained 'Buy' rating, signals increased confidence from Stifel in TXG's future performance and valuation. The new target implies a 17.1% upside from the stock's closing price on November 5, 2026, which is likely to be viewed positively by investors and could lead to short-term upward price momentum. For traders, this presents an opportunity to capitalize on potential price appreciation driven by analyst upgrades, though long-term performance will still depend on fundamental business execution and market conditions.

$TXG positive Price target raised, Buy rating maintained
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.